Literature DB >> 17083044

Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea.

Neha Pant1, Anna Hultberg, Yaofeng Zhao, Lennart Svensson, Qiang Pan-Hammarstrom, Kari Johansen, Peter H Pouwels, Franco M Ruggeri, Pim Hermans, Leon Frenken, Thomas Boren, Harold Marcotte, Lennart Hammarstrom.   

Abstract

BACKGROUND: Rotavirus-induced diarrhea poses a worldwide medical problem in causing substantial morbidity and mortality among children in developing countries. We therefore developed a system for passive immunotherapy in which recombinant lactobacilli constitutively express neutralizing variable domain of llama heavy-chain (VHH) antibody fragments against rotavirus.
METHODS: VHH were expressed in Lactobacillus paracasei, in both secreted and cell surface-anchored forms. Electron microscopy was used to investigate the binding efficacy of VHH-expressing lactobacilli. To investigate the in vivo function of VHH-expressing lactobacilli, a mouse pup model of rotavirus infection was used.
RESULTS: Efficient binding of the VHH antibody fragments to rotavirus was shown by enzyme-linked immunosorbent assay and scanning electron microscopy. VHH fragments expressed by lactobacilli conferred a significant reduction in infection in cell cultures. When administered orally, lactobacilli-producing surface-expressed VHH markedly shortened disease duration, severity, and viral load in a mouse model of rotavirus-induced diarrhea when administered both fresh and in a freeze-dried form.
CONCLUSIONS: Transformed lactobacilli may form the basis of a novel form of prophylactic treatment against rotavirus infections and other diarrheal diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17083044     DOI: 10.1086/508747

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  51 in total

1.  Screening and evaluation of human intestinal lactobacilli for the development of novel gastrointestinal probiotics.

Authors:  Piret Kõll; Reet Mändar; Imbi Smidt; Pirje Hütt; Kai Truusalu; Raik-Hiio Mikelsaar; Jelena Shchepetova; Kasper Krogh-Andersen; Harold Marcotte; Lennart Hammarström; Marika Mikelsaar
Journal:  Curr Microbiol       Date:  2010-05-05       Impact factor: 2.188

Review 2.  Bioengineered probiotics, a strategic approach to control enteric infections.

Authors:  Mary Anne Roshni Amalaradjou; Arun K Bhunia
Journal:  Bioengineered       Date:  2013-01-17       Impact factor: 3.269

3.  An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein.

Authors:  Abdolkarim Sheikhi; Mohammad Hojjat-Farsangi
Journal:  Hum Vaccin Immunother       Date:  2020-07-14       Impact factor: 3.452

4.  Monoclonal and Single Domain Antibodies Targeting β-Integrin Subunits Block Sexual Transmission of HIV-1 in In Vitro and In Vivo Model Systems.

Authors:  Janet Tai Guedon; Kun Luo; Hong Zhang; Richard B Markham
Journal:  J Acquir Immune Defic Syndr       Date:  2015-07-01       Impact factor: 3.731

5.  Oral enzyme therapy for celiac sprue.

Authors:  Michael T Bethune; Chaitan Khosla
Journal:  Methods Enzymol       Date:  2012       Impact factor: 1.600

6.  Development and Evaluation of a Novel VHH-Based Immunocapture Assay for High-Sensitivity Detection of Shiga Toxin Type 2 (Stx2) in Stool Samples.

Authors:  Luciano J Melli; Vanesa Zylberman; Yanina Hiriart; Constanza E Lauche; Ariela Baschkier; Romina Pardo; Elizabeth Miliwebsky; Isabel Chinen; Marta Rivas; Fernando A Goldbaum; Juan E Ugalde; Diego J Comerci; Andrés E Ciocchini
Journal:  J Clin Microbiol       Date:  2020-02-24       Impact factor: 5.948

7.  Integrative expression system for delivery of antibody fragments by lactobacilli.

Authors:  M Cruz Martín; Neha Pant; Victor Ladero; Gökçe Günaydin; Kasper Krogh Andersen; Beatriz Alvarez; Noelia Martínez; Miguel A Alvarez; Lennart Hammarström; Harold Marcotte
Journal:  Appl Environ Microbiol       Date:  2011-01-21       Impact factor: 4.792

8.  Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies.

Authors:  Kasper Krogh Andersen; Nika M Strokappe; Anna Hultberg; Kai Truusalu; Imbi Smidt; Raik-Hiio Mikelsaar; Marika Mikelsaar; Theo Verrips; Lennart Hammarström; Harold Marcotte
Journal:  Infect Immun       Date:  2015-11-16       Impact factor: 3.441

9.  Engineering of a human vaginal Lactobacillus strain for surface expression of two-domain CD4 molecules.

Authors:  Xiaowen Liu; Laurel A Lagenaur; Peter P Lee; Qiang Xu
Journal:  Appl Environ Microbiol       Date:  2008-06-06       Impact factor: 4.792

Review 10.  Single domain antibodies: promising experimental and therapeutic tools in infection and immunity.

Authors:  Janusz Wesolowski; Vanina Alzogaray; Jan Reyelt; Mandy Unger; Karla Juarez; Mariela Urrutia; Ana Cauerhff; Welbeck Danquah; Björn Rissiek; Felix Scheuplein; Nicole Schwarz; Sahil Adriouch; Olivier Boyer; Michel Seman; Alexei Licea; David V Serreze; Fernando A Goldbaum; Friedrich Haag; Friedrich Koch-Nolte
Journal:  Med Microbiol Immunol       Date:  2009-06-16       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.